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Abstract
Background: Lysosomal storage diseases (LSD) are inherited disorders caused by deficiency of lysosomal enzymes
in which early diagnosis is essential to provide timely treatment. This study reports interval values for the activity of
lysosomal enzymes that are deficient in Mucopolysaccharidosis type I, Fabry, Gaucher and Pompe disease, using
dried blood spots on filter paper (DBS) samples in a Brazilian population.
Results: Reference activity values were obtained from healthy volunteers samples for alpha-galactosidase A (4.57 ±
1.37 umol/L/h), beta-glucosidase (3.06 ± 0.99 umol/L/h), alpha-glucosidase (ratio: 13.19 ± 4.26; % inhibition: 70.66 ±
7.60), alpha-iduronidase (3.45 ± 1.21 umol/L/h) and beta-galactosidase (14.09 ± 4.36 umol/L/h).
Conclusion: Reference values of five lysosomal enzymes were determined for a Brazilian population sample.
However, as our results differ from other laboratories, it highlights the importance of establishing specific reference
values for each center.
Introduction
Lysosomal storage diseases (LSD) comprise a group of
more than 40 inherited disorders caused by deficiency
of specific lysosomal hydrolases, which results in the
accumulation of different macromolecules in the lyso-
some, leading to cell dysfunction and progressive clinical
manifestations [1,2].
Most LSD are inherited in an autosomal recessive
manner, with the exception of Hunter, Fabry and Danon
diseases that are X-linked. As a group, LSD have an
incidence of about 1 per 7700 live births [3].
For some LSD as Fabry, Gaucher and Pompe diseases
(FD, GD and PD respectively) and Mucopolysaccharido-
sis type I (MPS I), enzyme replacement therapy has
been widely used as a treatment option, improving the
quality of life and prognosis of these patients. Since
those diseases are all progressive, early diagnosis is an
essential tool for a successful treatment [2].
Biochemical diagnosis of LSD is performed by deter-
mination of enzymatic activities in different biological
fluids (as plasma, leukocytes, fibroblasts and most
recently dried blood spots on filter paper (DBS)), using
fluorimetry, immunocapture and mass spectrometry
assays [4-8]. One of the advantages for the use of DBS
in the diagnosis of LSD is that these samples may be
transported safely through long distances, including
mailing in regular envelopes, because enzyme activities
remain stable for months at room temperature [8]. In
addition, the preparation of a DBS sample requires only
a small amount of blood [9]. These advantages are espe-
cially important in large countries like Brazil, in which
there are few reference laboratories to perform these
assays.
Several studies have demonstrated the feasibility of
using DBS to diagnose LSD [9-11], but it is important to
establish specific reference values to each center, since
enzyme activity may vary due to specific characteristics
of each population and mainly because different assay
conditions. Therefore, the aim of this study was to estab-
lish a reference interval value for the activities of the fol-
lowing lysosomal enzymes in a Brazilian population
sample: alpha-galactosidase A (agal A), beta-glucosidase
(bglu), acid alpha-glucosidase (aglu), alpha-iduronidase
(aidua), which are used for the diagnosis of FD, GD, PD
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(bgal), used as a quality control tool.
Methods
This study was performed at Laboratório de Erros Inatos
do Metabolismo (LEIM) from Universidade Federal de
São Paulo (UNIFESP). Research protocols and consent
forms as well as the overall investigation were ethically
and scientifically approved by the Medical Research and
Ethical Committee of UNIFESP (0384/05).
Brazilian healthy volunteers (HV) between the ages of 18
and 80 and without a known genetic or chronic disease
were selected for our study. Samples were collected from
164 individuals (42% male and 58% female). Blood speci-
mens were collected by venipuncture into heparin tubes
and spotted on Whatman® 903 filter paper. Samples
collected at UNIFESP were dried at room temperature for
at least 4 hours and stored at the same day at 4°C in sealed
plastic bags with desiccant (to prevent hydration) until
analysis. Those collected at other locations were prepared
and dried in the same conditions (detailed instructions
were sent to those centers), sealed in plastic bags and sent
to the laboratory in a maximal interval of 5 days, where
they were stored at 4°C. Only high quality DBS, evaluated
by their macroscopic aspect (absence of jagged edges and
clots, and adequate amount of blood on the spot) and bio-
chemically by bgal activity [9,12] were used in this work.
DBS enzyme activity assays were adapted from the
methods described by Chamoles and coworkers [8,13-17].
agal A, aglu, aidua, bgal were assayed on microplates and
bglu was assayed on microtubes. For microplate assays,
1.5 mm diameter (1/16 inch) disks were punched from
each DBS and placed into separate wells in a 96-well blank
plate. For microtube assay, 3.0 mm diameter (1/8 inch)
disks were punched from DBS and placed into separate
2.0 mL microtubes. DBS removal from the wells/tubes
during the analysis was not necessary.
Reaction buffers, fluorogenic substrates, additional
reagents and incubation time used for each DBS assay
are described in Table 1. Assays were performed in
duplicate and with one blank per sample, which was
prepared by adding all reagents except the substrate.
The microplate/microtube reactions and substrate solu-
tion were incubated separately at 37°C in an orbital
shaker. After incubation, substrate solution was added
to blanks and the stop buffer was added to all wells/
tubes. The enzyme product 4-methylumbelliferone was
detected (excitation 365 nm; emission 450 nm) in a
fluorometer SpectraMax M2 (Molecular Devices). Fluor-
escence readings were corrected by blanks, and results
were compared to a 4-methylumbelliferone calibration
curve. Enzymatic activities were expressed as micro-
moles of hydrolyzed substrate per liter of blood per
hour (μmol/L blood/h), with the exception of aglu,
which was expressed as the ratio of neutral and lysoso-
mal isoforms (NaG/AaGIA) and % inhibition of total
acid fraction [9,17].
DBS samples from two healthy individuals have been
used as internal controls in every reaction as well as a
DBS from a confirmed patient. Within-assay coefficients
of variation (CVs) were calculated from an internal con-
trol sample analyzed in all assays.
Data are expressed as mean ± standard deviation (SD).
The parametric Student’s t test was performed to com-
pare mean activity values from both genders in HV
group. The level of significance for statistical analysis
was set at 0.05. All analyses were performed using the
software MINITAB® 15.1.1.0.
Results
bgal activity was analyzed in HV to establish its refer-
ence interval for our population and the range was 7.85
and 22.15 μmol/L blood/h (percentile 5 and 95 respec-
tively). bgal was used as control enzyme, and DBS sam-
ples with bgal activity lower or higher than the normal
range have not been included in this study, as they were
considered inappropriate. The mean, standard deviation
and interval values of the different enzymatic activities
are described in Table 2. A significant difference
between genders was observed for bglu (male: 2.82;
female: 3.23; p = 0.0053) and bgal activities (male: 12.61;
female: 15.17; p = 0.0001 respectively), which could be
due to the higher number of female subjects in the HV
group (69 males versus 95 females).
Our results differ from enzymatic activity values pre-
viously described by Chamoles and coworkers, especially
for aidua activity (our mean activity: 3.45; Chamoles
et al.: 5.50) [8,13-17]. Regarding the study from Cival-
lero and coworkers, in which several lysosomal enzymes
activities were evaluated in another Brazilian sample, a
difference in mean values was also observed, mainly for
bglu activity (our mean value: 3.09; Civallero et al.: 4.92)
[7]. This difference may be explained by sample size
issues, differences in equipment, chemicals or water or
even by ethnic diversity, once the Brazilian population is
known to be composed of a variety of ethnic back-
grounds [18]. However, these differences highlight the
importance of determining specific reference values for
each laboratory or reference center.
Within-assay CVs of internal controls were around
10%, interassay CVs did not exceed 20% and impreci-
sion data are in accordance with other related studies
[8,15,19,20].
Discussion
Different biological materials have been used to diag-
nose LSD patients, but recently several studies have
described the advantages of DBS [9,19,20]. These
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mail, even at room temperature, without altering
enzyme activity [14,15]. In addition, DBS minimizes bio-
logical hazards, since the blood is impregnated in the
filter paper and only a small amount of blood is
required to perform the assay. Moreover, these samples
do not require special storage conditions and the assay
on microplate is easier to perform and less expensive
than other techniques [8,9].
Although we did not evaluate newborns in this study,
it is known that this group has a higher range of enzyme
activity [7,8]. Therefore, it is important to emphasize
that a specific range must be taken into account when
analyzing newborn patients. In addition, it is important
to obtain a reference interval value for this particular
population if these assays would be included in newborn
screening programs.
It is also extremely important to emphasize that in
order to guarantee the quality of diagnosis, blood collec-
tion and DBS samples preparation must be done care-
fully, and the determination of a control enzyme, such
as bgal or hexosaminidase should be performed as a
quality control tool [9,12,14].
Although it has been demonstrated that these enzymes
activities are maintained stable on DBS samples, we sug-
gest that a sample from a healthy volunteer should be
sent to the laboratory for analysis along with the samples
of clinically suspected patients, which could point out
any unexpected decrease of the enzymes activities during
transportation [8,9]. Therefore, the establishment of
reference values from healthy volunteers could be useful
as an additional quality control tool for DBS assays.
We believe that the determination of enzyme activity
using DBS samples is the best option for screening
patients with LSD, especially in high risk groups. This
alternative has several advantages that outweigh an
initial evaluation of suspected subjects using DBS sam-
ples. However, as some of our results differ from other
laboratories, it highlights the importance of establishing
specific reference values for each reference center.
The establishment of reference values for lysosomal
enzyme activities on DBS in a Brazilian population may
Table 1 Assay conditions for each enzyme activity assay
ENZYME Punch
diameter
Reaction buffer Fluorogenic substrate Additional reagents Incubation
time
Stop buffer
alpha-
galactosidase A
1.5 mm 30 μL citrate-phosphate
0.3 M pH 5.0
30 + 30* μL
4 MU-alpha-D-
galactopyranoside 4.2
mM
10 μL
N-acetyl-galactosamine
0.25 M
20 hours 10%
ethylenediamine
1.32 M pH 11.3
alpha-iduronidase 1.5 mm 10 μL
sodium formate 0.2 M pH
2.8
20 + 20* μL
4MU-alpha-L-
idopyranoside
2m M
10 μL
D-saccharic acid
1,4-lactone monohydrate
3m M
20 hours 10%
ethylenediamine
1.32 M pH 11.3
beta-glucosidase 3.0 mm 30 μL citrate-phosphate
0.4 M pH 5.2
50 + 50* μL
4MU-beta-D-
glycopyranoside 20 mM
40 μL
sodium taurodeoxicolate
hydrate 0.75%
20 hours 10%
ethylenediamine
1.32 M pH 11.3
alpha-glucosidase 1.5 mm 20 μL
sodium acetate 0.4 M pH
4.0 and 6.5
20 + 20* μL
4MU-alpha-D-
glycopyranoside 2.8 mM
40 μL
acarbose 40 μM
24 hours 10%
ethylenediamine
1.32 M pH 11.3
beta-galactosidase 1.5 mm 20 μL citrate-phosphate
0.1 M pH 4.4
20 + 40* μL
4MU-beta-D-
galactopyranoside 0.8
mM
20 μL sodium chloride
0.9%
3 hours 10%
ethylenediamine
1.32 M pH 11.3
* addition in blank wells after incubation.
MU: methylumbilliferyl.
Table 2 Enzyme activities from HV DBS samples
a-gal A a-idua NaG/AaGIA % inhibition b-glu b-gal
n 164 164 164 164 156 164
mean 4.57 3.45 13.19 70.66 3.06 14.09
SD 1.37 1.21 4.26 7.60 0.99 4.36
interval 1.44 - 10.67 1.40 - 7.78 5.03 - 28.58 36.38 - 87.08 1.51 - 7.23 4.04 - 29.65
Data expressed as μmol/L blood/h.
n = number of samples.
SD = standard deviation.
Interval = established as minimum to maximum.
% inhibition = percent of other alpha-glucosidase isoforms inhibition.
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in our country, and even enable the implantation of a
newborn screening program.
Acknowledgements
We would like to thank: students and technicians from LEIM, all individuals
who agreed to participate and the physicians. We wish to express our
gratefulness to FAPESP (K.B.M. scholarship), CAPES (V.G.P scholarship), CNPq
(process n° # 501248/2005-6), AFIP and IGEIM. V.D’A. is recipient of CNPq
researcher fellowship.
Author details
1Department of Pediatrics - Universidade Federal de São Paulo (UNIFESP),
São Paulo, Brazil.
2Department of Biosciences - Universidade Federal de São
Paulo (UNIFESP), Santos, Brazil.
Authors’ contributions
KBM, MDBR and VGP participated in the collection of samples, determination
of enzyme activities, analysis and interpretation of data and drafting the
manuscript. AMM helped with samples collection and the design of the
study. VD participated in the design of the study, its coordination and
critically revised the manuscript. All authors have read and approved the
final manuscript version.
Competing interests
The authors declare that they have no competing interests.
Received: 6 August 2010 Accepted: 29 September 2010
Published: 29 September 2010
References
1. Scriver CRBAL, Sly WS, Valle D, Childs R, Kinzler KW: The Metabolic Basis of
Inherited Disease New York: McGraw-Hill 2001.
2. Platt FM, Lachmann RH: Treating lysosomal storage disorders: current
practice and future prospects. Biochim Biophys Acta 2009, 1793:737-745.
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal
storage disorders. JAMA 1999, 281(3):249-254.
4. Omura K, Higami S, Tada K: alpha-L-iduronidase activity in leukocytes:
diagnosis of homozygotes and heterozygotes of the Hurler syndrome.
Eur J Pediatr 1976, 122:103-105.
5. Gelb MH, Turecek F, Scott CR, Chamoles NA: Direct multiplex assay of
enzymes in dried blood spots by tandem mass spectrometry for the
newborn screening of lysosomal storage disorders. J Inherit Metab Dis
2006, 29:397-404.
6. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ:
Immunoquantification of alpha-galactosidase: evaluation for the
diagnosis of Fabry disease. Clin Chem 2004, 50:1979-1985.
7. Civallero G, Michelin K, de Mari J, Viapiana M, Burin M, Coelho JC,
Giugliani R: Twelve different enzyme assays on dried-blood filter paper
samples for detection of patients with selected inherited lysosomal
storage diseases. Clin Chim Acta 2006, 372:98-102.
8. Chamoles NA, Blanco MB, Gaggioli D, Casentini C: Hurler-like phenotype:
enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 2001,
47:2098-2102.
9. Gasparotto N, Tomanin R, Frigo AC, Niizawa G, Pasquini E, Blanco M,
Donati MA, Keutzer J, Zacchello F, Scarpa M: Rapid diagnostic testing
procedures for lysosomal storage disorders: alpha-glucosidase and beta-
galactosidase assays on dried blood spots. Clin Chim Acta 2009, 402(1-
2):38-41.
10. Kallwass H, Carr C, Gerrein J, Titlow M, Pomponio R, Bali D, Dai J, Kishnani P,
Skrinar A, Corzo D, Keutzer J: Rapid diagnosis of late-onset Pompe
disease by fluorometric assay of alpha-glucosidase activities in dried
blood spots. Mol Genet Metab 2007, 90:449-452.
11. Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH:
Direct multiplex assay of lysosomal enzymes in dried blood spots for
newborn screening. Clin Chem 2004, 50:1785-1796.
12. Lukacs Z, Keil A, Peters V, Kohlschutter A, Hoffmann GF, Cantz M, Kopitz J:
Towards quality assurance in the determination of lysosomal enzymes: a
two-centre study. J Inherit Metab Dis 2003, 26:571-581.
13. Chamoles NA, Blanco M, Gaggioli D, Casentini C: Gaucher and Niemann-
Pick diseases–enzymatic diagnosis in dried blood spots on filter paper:
retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002,
317:191-197.
14. Chamoles NA, Blanco MB, Iorcansky S, Gaggioli D, Specola N, Casentini C:
Retrospective diagnosis of GM1 gangliosidosis by use of a newborn-
screening card. Clin Chem 2001, 47:2068.
15. Chamoles NA, Blanco M, Gaggioli D: Fabry disease: enzymatic diagnosis in
dried blood spots on filter paper. Clin Chim Acta 2001, 308:195-196.
16. Chamoles NA, Blanco M, Gaggioli D: Diagnosis of alpha-L-iduronidase
deficiency in dried blood spots on filter paper: the possibility of
newborn diagnosis. Clin Chem 2001, 47:780-781.
17. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C: Glycogen
storage disease type II: enzymatic screening in dried blood spots on
filter paper. Clin Chim Acta 2004, 347:97-102.
18. WHO: Hereditary Diseases Programme: guidelines for the development
of national programmes for monitoring birth defects. 1993, 11-12, WHO/
HDP/ICBDMS/GL/93.4 (54 pp.).
19. Olivova P, van der Veen K, Cullen E, Rose M, Zhang XK, Sims KB, Keutzer J,
Browning MF: Effect of sample collection on alpha-galactosidase A
enzyme activity measurements in dried blood spots on filter paper. Clin
Chim Acta 2009, 403:159-162.
20. De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, Muhl A, Orsini JJ,
Caggana M, Vogt RF, Hannon WH: Development and evaluation of quality
control dried blood spot materials in newborn screening for lysosomal
storage disorders. Clin Chem 2009, 55:158-164.
doi:10.1186/1746-1596-5-65
Cite this article as: Müller et al.: Reference values for lysosomal enzymes
activities using dried blood spots samples - a Brazilian experience.
Diagnostic Pathology 2010 5:65.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Müller et al. Diagnostic Pathology 2010, 5:65
http://www.diagnosticpathology.org/content/5/1/65
Page 4 of 4